GEMP vs. GANX, AADI, CKPT, NBRV, EQ, HCWB, EGRX, RMTI, BLRX, and BOLT
Should you be buying Gemphire Therapeutics stock or one of its competitors? The main competitors of Gemphire Therapeutics include Gain Therapeutics (GANX), Aadi Bioscience (AADI), Checkpoint Therapeutics (CKPT), Nabriva Therapeutics (NBRV), Equillium (EQ), HCW Biologics (HCWB), Eagle Pharmaceuticals (EGRX), Rockwell Medical (RMTI), BioLineRx (BLRX), and Bolt Biotherapeutics (BOLT). These companies are all part of the "medical" sector.
Gemphire Therapeutics (NASDAQ:GEMP) and Gain Therapeutics (NASDAQ:GANX) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their valuation, analyst recommendations, institutional ownership, media sentiment, profitability, community ranking, risk, earnings and dividends.
Gemphire Therapeutics received 267 more outperform votes than Gain Therapeutics when rated by MarketBeat users. Likewise, 69.98% of users gave Gemphire Therapeutics an outperform vote while only 61.11% of users gave Gain Therapeutics an outperform vote.
17.5% of Gemphire Therapeutics shares are owned by institutional investors. Comparatively, 12.0% of Gain Therapeutics shares are owned by institutional investors. 22.7% of Gemphire Therapeutics shares are owned by insiders. Comparatively, 11.0% of Gain Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.
Gemphire Therapeutics has a beta of 2.82, suggesting that its share price is 182% more volatile than the S&P 500. Comparatively, Gain Therapeutics has a beta of 0.52, suggesting that its share price is 48% less volatile than the S&P 500.
Gain Therapeutics' return on equity of -193.03% beat Gemphire Therapeutics' return on equity.
Gain Therapeutics has higher revenue and earnings than Gemphire Therapeutics.
In the previous week, Gain Therapeutics had 1 more articles in the media than Gemphire Therapeutics. MarketBeat recorded 1 mentions for Gain Therapeutics and 0 mentions for Gemphire Therapeutics. Gain Therapeutics' average media sentiment score of 1.48 beat Gemphire Therapeutics' score of 0.00 indicating that Gain Therapeutics is being referred to more favorably in the news media.
Gain Therapeutics has a consensus price target of $8.50, suggesting a potential upside of 187.16%. Given Gain Therapeutics' higher possible upside, analysts clearly believe Gain Therapeutics is more favorable than Gemphire Therapeutics.
Summary
Gain Therapeutics beats Gemphire Therapeutics on 8 of the 13 factors compared between the two stocks.
Get Gemphire Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for GEMP and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding GEMP and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Gemphire Therapeutics Competitors List
Related Companies and Tools
